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Phyllanthus niruri L. (Euphorbiaceae), known as “quebra-pedra” (Portuguese for “stonebreaker”), is an 
herb used for kidney disorders. In light of its frequent use by the population, the present study aimed to 
investigate the genotoxic, antigenotoxic and cytotoxic activities of a standardized P. niruri extract in bone 
marrow rats. Three groups of 12 animals were treated daily by gavage over a period of 30 days, with 50, 
150 or 250 mg/kg of P. niruri extract aqueous solution. The control group (n = 12) received tap water. At 
the end of treatment (day 31), groups were divided into two minor subgroups (n=6/group) and received 
cyclophosphamide (50 mg/kg, i.p.) or saline 0.9% (i.p.). After 24 hours, we evaluated the frequency 
of micronucleated polychromatic erythrocytes for each animal (MNPCE) at 1000 PCE. Cytotoxicity 
was evaluated with the PCE/NCE ratio (NEC = normochromatic erythrocytes). General toxicity was 
assessed during treatment using the parameters of body weight gain, ration and water consumption. The 
dry extract did not provoke changes in body weight, weight gain, ration and water intake or changes 
in the frequency of MNPCE or cytotoxicity in bone marrow. We propose that the P. niruri extract used 
here showed no genotoxic, antigenotoxic and cytotoxic activities under the experimental conditions.
Uniterms: Phyllanthus niruri L./genotoxicity. Phyllanthus niruri L./toxicological analysis/experimental 
study. Medicinal plantas/evaluation.
Phyllanthus niruri L. (Euphorbiaceae), conhecida como “quebra-pedra”, é uma planta medicinal utilizada 
frequentemente pela população no tratamento de problemas renais. Foram avaliadas as atividades 
genotóxicas, antigenotóxicas e citotóxicas de um extrato padronizado dessa espécie em ratos. Três 
grupos de doze animais foram tratados durante trinta dias, por gavagem, com 50, 150 ou 250 mg/kg/dia  
de solução aquosa do extrato de P. niruri e um grupo controle (n=12) recebeu água destilada pela 
mesma via. No final do tratamento os grupos foram divididos em dois subgrupos (6 animais/grupo) e 
receberam uma dose única de ciclofosfamida (50 mg/kg, i.p.) ou de solução salina 0,9% (i.p.). Após 24 
horas, a frequência de eritrócitos policromáticos micronucleados (EPCMN) foi avaliada em 1000 EPC. 
A citotoxicidade foi avaliada pela relação entre eritrócitos policromáticos e normocromáticos (EPC/
ENC) e a toxicidade geral foi avaliada através dos parâmetros de ganho de peso corporal, consumo de 
ração e ingestão hídrica. O extrato seco não provocou alterações significativas no peso corporal, ganho 
de peso e consumo de ração em relação ao grupo controle, nem alterações na frequência de EPCMN ou 
citotoxicidade em medula óssea. Dessa maneira, pode-se concluir que P. niruri não apresentou atividades 
genotóxica, antigenotóxica e/ou citotóxica nas condições experimentais executadas.
Unitermos: Phyllanthus niruri L./genotoxicidade. Phyllanthus niruri L./análise toxicological/estudo 
experimental. Plantas medicinais/avaliação.
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INTRODUCTION
Medicinal plants and their preparations have been 
used to treat several illnesses since the dawn of human 
history and are one of the foundations for healthcare 
worldwide (AESGP, 1998; Turolla, 2004; Mendes; Her-
deiro; Pimentel, 2010). The observation and experience 
of primitive man elucidated the therapeutic properties of 
certain plants and promoted their use from one generation 
to another (Turolla, 2004).
It is well known that natural products traditionally 
consumed by a portion of the population may have muta-
genic potential. As such, further evaluation and studies are 
needed in order to confirm this possibility (Freitas, 2007).
The species Phyllanthus niruri Linné, commonly 
known as “erva-pombinha”, “quebra-pedras-de-ar-
vorezinha”, “quebra-pedra”, “quebra-pedra legítimo” or 
“quebra-pedra verdadeiro” (names in Portuguese for the 
herb stonebreaker) (Simões et al., 1986; Garlet, 2000), 
belongs to the family Euphorbiaceae, which contains ap-
proximately three hundred and fifteen genera and eight 
thousand species (Filho et al., 1996). The herb has a thin 
straight stalk with many branches, is between 10 and 
30 cm tall (Franco, 1997; Santos, Torres, Leonart, 1987) 
and can be found in Africa, Asia and the Americas, com-
monly on coastal plains (Castro-Chaves et al., 2002). 
In addition to alkaloids, other compounds including 
tannins, flavonoids, phenols, triterpenoids, fatty acids, 
esters of phthalic acid, lignins such as phyllanthin and 
hypophyllanthin, and vitamin C have been isolated and 
characterized in several species of the genus Phyllanthus 
(Ahmad, Husain, Osman, 1981; Miguel et al., 1996; 
Quian-Cutrone, 1996; Ueno et al., 1988; Ishimaru et 
al., 1992; Rajeshkumar et al., 2002; Mahdi et al., 2011; 
Samali et al., 2012). Studies with P. niruri have found 
flavonoids such as quercetin and kaempferol (El-Mekkawy 
et al., 1995), lignin glycosides called phyllanthostatin A, 
1 and 2 (Pettit, Schaufelberger, 1988; Pettit et al., 1990), 
ellagitannins such as geraniin and furosin (Miguel et al., 
1996), niruroidine (Quian-Cutrone et al., 1996), lignans 
as nirtetralin A and B (Wei et al., 2012) among others.
In folk medicine, P. niruri is mainly used for urinary 
tract problems, such as kidney and bladder pain, renal li-
thiasis, and as a diuretic (Garlet, 2000). Extracts of P. niruri 
were found to normalize high levels of urinary calcium, 
reducing the formation of calculus in patients (Nishiura et 
al., 2004). This suggests it interferes in the first stages of 
stone formation and may be an alternative in the treatment 
and/or prevention of urolithiasis and inhibit the formation 
of calcium oxalate crystals in the urinary tract, preventing 
renal calculus (Barros et al., 2003; Freitas, Schoe, Boim, 
2002). Studies show that the plant promotes relaxation of 
the ureters which, combined with analgesic action (Santos 
et al., 1995), facilitates the descent of stones. This generally 
occurs without pain or bleeding and increases glomerular 
filtration and the excretion of uric acid (Lorenzi; Matos, 
2002), justifying its use for renal lithiasis. The aqueous 
extract inhibits reverse transcriptase in the human immu-
nodeficiency virus type 1 (HIV-1-RT) (Ogata et al., 1992; 
El-Mekkawy et al., 1995; Notka, Meier, Wagner, 2003). 
However, other studies have been conducted in an attempt 
to prove several other biological activities, such as analgesic 
action (Miguel et al., 1996; Santos et al., 1995; Santos et 
al., 2000), anti-tumor activity in different cell lines (Powis, 
Moore, 1985; Pettit, Schaufelberger, 1988; Pettit et al., 
1990; Rajeshkumar, Kuttan, 2000), antioxidant effects in 
preventing gastric ulcers (Bandyopadhay, Pakrashi, 2000), 
anti-inflammatory (Ignácio et al., 2001; Kiemer et al., 2003) 
and anti-malaria activity (Muñoz et al., 2000) and reduced 
plasma lipid levels in rats (Khanna, Rizvi, Chander, 2002). 
It also exhibits abortive and purgative action in large doses 
(Martins et al., 1994). Manjrekar et al. (2008) demonstrated 
a reduction in carbon tetrachloride-induced hepatotoxic 
effects in rats treated with an aqueous extract of P. niruri.
The use of herbal drugs has long been well known. 
In order to popularize this knowledge and clarify when 
and how these drugs should be used to achieve benefi-
cial effects, the National Agency for Sanitary Vigilance 
(ANVISA) provides notification of herbal drugs through 
Resolution-RDC Nº 10 of March 9, 2010 (Brasil, 2010). 
Standardization for popular use of P. niruri as an herbal 
drug among adults is 3 g (equivalent to a soup spoon) in-
fused with 150mL of water (1 teacup), 2 or 3 times a day. 
It is recommended for renal lithiasis to help remove small 
kidney stones but contraindicated for large stones, as well 
as during pregnancy. Main adverse reactions include diar-
rhea and hypotension and it should not be used for more 
than three weeks (Brasil, 2010).
Among genotoxicity tests recommended by inter-
national regulatory agencies and government institutions, 
the in vivo Micronucleus Test (MN) in rat bone marrow is 
widely accepted and recommended to assess and record 
new chemical and pharmaceutical products that enter the 
world market (Krishna, Hayashi, 2000; Ribeiro, 2003; 
Speit, Zeller, Neuss, 2011). This test is frequently used to 
detect clastogenic agents (which break chomosomes) and 
aneugenic agents (which induce aneuploidy or abnormal 
chromosome segregation due to mitotic spindle dysfunc-
tion) (Macgregor et al., 1987; Hayashi et al.; 1994). It 
was initially developed in mouse bone marrow erythro-
cytes (Schmid, 1976), but can also be performed on rats 
(George, Wooton, Gatehouse, 1990).
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In the present study, three different concentrations 
of dry P. niruri were tested to assess in vivo genotoxic, 
antigenotoxic and cytotoxic activities in the bone marrow 
cells of Wistar rats, using MN tests as a parameter. General 
toxicity was also evaluated after 30-day treatment with 
aqueous suspension of dry P. niruri extract.
MATERIAL AND METHODS
Materials
Dry P. niruri extract (lot: 024827, supplier: FLORES 
E ERVAS) was obtained from a compounding pharmacy in 
the city of Natal and suspended in water at a concentration 
of 20 mg/mL. Total tannin and gallic acid content in the lot 
used was 6.5% and 0.15% respectively, in accordance with 
supplier specifications. Cyclophosphamide was acquired 
from Sigma Chemical Co., USA; methanol (Merck); Gi-
emsa (Merck); May-Grunwald (Merck); saline solution 
(NaCl 0.9%).
Animals
Adult male rats (48) with an initial weight of 280g 
were obtained from the vivarium of the Health Sciences 
Center at the Federal University of Rio Grande do Norte 
(UFRN). Individuals were from the same strain of the spe-
cies Rattus novergicus, family Wistar, and were randomly 
separated into four groups (n = 12/group). Over a period 
of 30 days, three experimental groups received doses of 
50, 150 and 250 mg/kg/day of dry P. niruri extract, by 
gavage, suspended in distilled water. The control group 
received only water, using the same method and time pe-
riod. Body weight, ration consumption and water intake 
were monitored during treatment and weight gain was 
also calculated. Animals were housed in polypropylene 
cages with metal lids measuring 40 x 50 x 20 cm, for no 
less than 5 days before being submitted to the different 
experimental conditions. Individuals were kept in a room 
at approximately constant temperature (23 to 26 °C) in a 
12 hour light/dark cycle, where lights were turned on at 
6.00 h. Water and feed (Labina® - Purina) were offered ad 
libitum throughout the experimental process. The research 
project was approved by the Ethics Committee on Animal 
Use at the Federal University of Rio Grande do Norte 
(CEUA – UFRN) under protocol number 024/2010. The 
methodology used was in accordance with guidelines of 
the Brazilian Animal Experimentation College (COBEA) 
and standards described in Law nº 11.794/2008.
Doses adopted were calculated considering the 
recommended dose for use in human adults to treat renal 
lithiasis; around 130 mg/kg/day (Brasil, 2010). Thus, a 
smaller, a similar and a larger dose were used to evaluate 
general toxicity.
Genotoxicity assessment by the MN test in mouse 
bone marrow
At the end of the 30-day treatment, animals from 
experimental and control groups were subdivided into 
smaller groups of six animals each. One of the new smaller 
groups for each treatment received 0.9% saline solution 
i.p. (at a volume of 1.0 mL) and the remaining groups 
received 50mg/kg i.p of cyclophosphamide. 
After 24 hours of the above treatments, animals were 
euthanized with sodium thiopental (50mg/kg i.p.) and 
the femur was aseptically exteriorized and removed. The 
Schmid method (1976) was used to obtain bone marrow 
cells for the MN frequency study, modified by Zambrano, 
Targa and Rabello-Gay (1982). The far end of the proximal 
femur was cut to expose the spinal canal. Next, a syringe 
needle previously filled with 1.0 mL of 0.9% sterile saline 
solution was inserted firmly into the opening, injecting the 
serum and extracting the cells from the femoral cavity of 
each animal. Cells were place in 15 mL conical centrifuge 
tubes.
Slide preparation for MN research
Centrifuge tubes containing the bone marrow cells 
were centrifuged for 5 minutes at 1000 rpm, discarding 
the supernatant. From the resulting suspension, a small 
drop was transferred to a glass slide for distension. Two 
smears were performed per animal and slides were kept 
at room temperature for drying. May-Grunwald-Giemsa 
stain was used, modified by Rosenfeld. Staining allowed 
for differentiation between polychromatic (PCE) and 
normochromatic erythrocytes (NCE). Genotoxic and an-
tigenotoxic activity was assessed on an optical microscope 
with a 100x objective lens (zigzag orientation), using the 
frequency of micronucleated polychromatic erythrocytes 
(MNPCE) in 1000 polychromatic erythrocytes, for each 
animal. We also determined the polychromatic erythrocyte 
count in 200 total erythrocytes (PCE + NCE) by the PCE/
NCE ratio in order to confirm the presence of cytotoxicity.
Statistical analysis
Data were assessed with the analysis of variance 
(ANOVA) method and the Tukey-Kramer test, when nec-
essary. Data were considered statistically significant for 
all groups when P<0.05.
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RESULTS
Statistical analysis revealed no changes in body 
weight (Table 1) and food consumption (Figure 1) for ani-
mals treated with P. niruri when compared with controls. 
However, body weight gain was lower in the group treated 
with a dose of 150 mg/kg/day from the first to the sixth day 
of treatment [F(3/44)= 3.790; p<0.05] and over the entire 
treatment period [F(3/44)= 2.961; p<0.05] (Figure 2). 
Only isolated alterations in water intake were detect-
ed (Figure 3). Statistical analysis revealed reduced water 
consumption in groups treated with doses of 50 mg/kg/day 
TABLE I - Body weight (g) of male rats treated or not (control) with different doses of dry P. niruri extract (50, 150 or 250 mg/kg/day; 
p.o.) for 31 days. Means and the respective standard errors are shown (n= 12/group)
Day of treatment Control P. niruri 50 mg/kg/day P. niruri 150 mg/kg/day P. niruri 250 mg/kg/day
1 269.42 ± 13.02 291.00 ± 10.36 278.75 ± 12.36 279.75 ± 9.34
3 277.58 ± 10.55 293.42 ± 10.14 291.92 ± 17.47 279.75 ± 10.03
5 281.08 ± 10.22 293.92 ± 10.15 277.50 ± 12.44 283.83 ± 10.13
7 283.92 ± 9.03 286.17 ± 7.32 279.00 ± 12.60 286.83 ± 9.28
9 288.08 ± 9.07 294.92 ± 9.85 280.92 ± 12.90 285.92 ± 9.67
11 290.17 ± 8.84 296.08 ± 9.92 281,33 ± 12.43 289.50 ± 8.97
13 290.50 ± 9.04 298.83 ± 10.08 280.83 ± 12.73 290.50 ± 9.26
15 293.92 ± 8.13 297.92 ± 10.29 281.17 ± 12.49 291.67 ± 9.28
17 292.58 ± 7.87 300.75 ± 10.72 283.83 ± 12.70 292.83 ± 9.21
19 296.08 ± 8.35 302.58 ± 10.69 284.83 ± 12.53 294.17 ± 9.87
21 298.67 ± 8.27 305.00 ± 10.39 288.50 ± 12.89 295.75 ± 9.78
23 299.58 ± 7.31 306.50 ± 10.40 288.58 ± 12.77 298.00 ± 9.38
25 293.83 ± 10.72 308.50 ± 10.69 288.92 ± 13.10 300.25 ± 9.45
27 303.92 ± 7.73 310.17 ± 10.60 291.42 ± 12.85 300.25 ± 9.39
29 304.25 ± 7.37 310.42 ± 10.64 292.00 ± 12.81 301.75 ± 9.85
31 305.00 ± 7.13 313.92 ± 10.69 294.58 ± 12.97 303.50 ± 9.68
P>0.05; ANOVA
FIGURE 1 - Feed intake (g) of male rats treated or not (control) with different doses of dry P. niruri extract (50, 150 or 250 mg/kg/day; 
p.o.) for 31 days. The above values represent the mean and respective standard error for each group (p>0.05; ANOVA).
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FIGURE 2 - Weight gain (g) among male rats treated or not (control) with different doses of dry P. niruri extract (50, 150 or 250 
mg/kg/day; p.o.) for 31 days. The above values represent the mean and respective standard error for each group. (ANOVA, Tukey-
Kramer Test, *p<0.05 in relation to the control group).
FIGURE 3 - Water intake (ml) for male rats treated or not (control) with different doses of dried P. niruri extract (50, 150 or 
250 mg/kg/day; p.o.) for 31 days. The above values represent the mean and respective standard error for each group. ANOVA, 
Tukey-Kramer test, *p<0.05, **p<0.01 in relation to the control.
[F(3/44)= 5.976; p<0.05] and 150 mg/kg/day [F(3/44)= 
5.976; p<0.05] during day 9 of treatment and by the group 
treated with the larger dose on day 7 [F(3/44)= 2.884; 
p<0.05], 9 [F(3/44)= 5.976; p<0.01] and 27 [F(3/44)= 
5.285; p<0.01].
When evaluating the mutagenicity of dry P. niruri 
extract, the animals treated only with this extract exhibited 
a statistically lower MN frequency in relation to the posi-
tive control group [F(7/40)= 24.762; p<0.001]. Groups 
treated with P. niruri and cyclophosphamide showed an 
increase in MN frequency in relation to negative controls 
[F(7/40)= 24.762; p<0.001] and a decrease in this param-
eter in comparison to groups treated only with P. niruri 
[F(7/40)= 24.762; p<0.001]. This behavior is similar to 
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groups treated only with cyclophosphamide, which display 
an increase in MNPCE frequency in relation to negative 
controls [F(7/40)= 24.762; p<0.001] (Figure 4).
Cytotoxicity evaluation of bone marrow erythro-
cytes showed animals treated with the extract exhibited a 
statistically higher PCE/NCE ratio when compared with 
positive controls (Figure 5). This is similar to the nega-
tive control group, indicating a lack of cytotoxicity in the 
extract.
DISCUSSION
Toxicological assessment of plant extracts is a mean 
of investigating possible collateral effects and establishing 
their safe use by the population.
According to Barros et al. (2005), there is great 
concern about the safe use of plant extracts. Freitas (2007) 
underscores that natural products traditionally consumed 
by the population need further study, since they may 
FIGURE 4 - Evaluation of micronuclei frequency in polychromatic erythrocytes (PCE) in the bone marrow of rats (n=6/group) 
exposed to different doses of dry P. niruri extract (50, 150 or 250 mg/kg/day; p.o.). The positive control group received a single 
dose of cyclophosphamide (CF) (50 mg/kg; i.p.). The above values represent the mean and standard error for each group a, b, c, d 
(p<0.001, ANOVA followed by the Tukey-Kramer test). (a) positive control vs negative control; (b) P. niruri vs positive control; 
(c) P. niruri + cyclophosphamide vs negative control; (d) P. niruri + cyclophosphamide vs P. niruri.
FIGURE 5 - Evaluation of the polychromatic/normochromatic ratio (PCE/NCE) in the bone marrow of rats (n=6/goup) exposed 
to different doses of dry P. niruri extract (50, 150 or 250 mg/kg/day; p.o.). The positive control group received a single dose of 
cyclophosphamide (CF) (50 mg/kg; i.p.). The above values represent the mean and standard error for each group a, b, c, d (p<0.001, 
ANOVA followed by the Tukey-Kramer test). (a) positive control vs negative control; (b) P. niruri vs positive control; (c) P. niruri 
+ cyclophosphamide vs negative control; (d) P. niruri + cyclophosphamide vs P. niruri.
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be mutagenic. In order to ensure the quality and safety 
of phytomedicines, the Brazilian National Agency of 
Sanitary Vigilance (ANVISA) published resolution no. 17 
(Brazil, 2000) on 24 February 2000, decreed that they must 
be submitted to preclinical and clinical toxicological trials.
In this study general bone marrow toxicity, geno-
toxicity and cytotoxicity were assessed, using the micro-
nucleus test in rats fed dry P. niruri L extract.
Nwanjo (2006) evaluated acute toxicity of aque-
ous extract of P. niruri leaves in Wistar rats after treat-
ment with doses between 250 and 1,500 mg/kg of body 
weight (i.p.), obtaining a DL50 of 516.2 mg/kg. Asare 
et al. (2012) observed, in a study developed with adult 
Sprague Dawley rats, that an ethanolic extract obtained 
from P. niruri was not acutely toxic at 3,000 mg/kg. Stud-
ies in mice revealed low toxicity in the aqueous extract 
of P. niruri, intraperitoneally administered at a dose of 
1.8 mg/kg/day, showing no body weight loss after three 
days of treatment and a slight weight gain after seven 
days of treatment (Venkateswaran, Millman, Blumberg, 
1987). Tona et al. (2001) demonstrated that aqueous and 
ethanol extract of P. niruri orally administered to mice 
at a dose of 500 mg/kg of body weight, once a week, for 
4 weeks, caused no toxic effects or deaths. In our study, 
we observed a slight reduction of water intake (Figure 3) 
in rats treated with doses of 150 and 250 mg/kg/day of 
P. niruri when compared to the control group. However, 
we found no alterations in body weight (Table I), in body 
weight gain (Figure 1) or food consumption (Figure 2) 
in animals treated with P. niruri extract, corroborating 
the data of the abovementioned studies. These data are 
insufficient to confirm or not the toxicity of chemical 
substances; however, basic parameters allow us to suggest 
or not their toxicity. Several other tests, such as the serum 
and/or plasma investigation of biochemical parameters, 
as well as histopathological, genotoxic, mutagenic and 
behavioral studies, are important for a more consistent 
determination of chemical compound toxicity. A study 
recently developed (Asare et al., 2012) observed that an 
ethanolic extract obtained from P. niruri whole plant was 
not toxic to adult rats treated during 90 days with 30 and 
300 mg/kg. Hematological, biochemical or histopathologi-
cal alterations were not observed in rats treated with the 
higher dose. However, the lower dose promoted lympho-
cyte reduction and drastic reduction was observed in most 
liver function test param eters (bilirubin, AST and ALT), 
suggesting some degree of hepatoprotection. Otherwise, 
the authors conclude that the P. niruri whole plant ethano-
lic extract is generally non-toxic. This data corroborates 
with the findings in the actual study where the three doses 
(50, 150 and 250 mg/kg) of the aqueous extract obtained 
from P. niruri dry leaves were sufficient to promote mild 
toxicity to rats treated during 30 days.
Antioxidant activity of P. niruri was reported by 
Harish and Shivanandappa (2006). Aqueous and methanol 
extracts at a dose of 100 mg/kg of body weight were cited 
as potent inhibitors of Fe2+ and ascorbate-induced micro-
somal lipid peroxidation; inhibitors of superoxide radical 
formation; and DPPH radical scavengers in in vitro stud-
ies. According to the authors, this antioxidant potential was 
responsible for inhibiting carbon tetrachloride-induced 
lipid peroxidation in rat livers. Shyamasundar et al. (1985) 
demonstrated that chemical components such as phyl-
lanthin and hypophyllanthin could protect against carbon 
tetrachloride (CCL4) cytotoxicity in primary cultures of 
isolated hepatocytes. 
The cytotoxicity of a substance can be assessed by 
the PCE/NCE ratio. According to Mavournin et al. (1990), 
the ratio between PCE and NCE frequency decreases 
when replacement of PCEs originating in erythroblasts 
is lowered. Results show that there was no statistically 
significant decrease in the PCE/NCE ratio in the groups 
treated only with dry extract of P. niruri compared to 
negative control in all doses (p>0.05). The PCE/NCE 
ratio obtained for each dose of extract was similar to that 
found for the negative control group and quite different 
from that observed in the positive control group (Figure 
5). Moreover, dry extract demonstrated no protective ac-
tion against cyclophosphamide-induced cytotoxicity in rat 
bone and the PCE/NCE ratio fell in groups treated with 
P. niruri and cyclophosphamide. In the present study dry 
extract of P. niruri exhibited no cytotoxic activity under 
the experimental conditions used. 
MNs appear in daughter cells, due to damage in-
duced in parental cells (Ribeiro, 2003). The two basic 
phenomena that result in MN formation in mitotic cells 
are chromosomal breakage and nondisjunction of the 
mitotic apparatus. MNs are formed from acentric or 
chromatid chromosomal fragments that are delayed in 
the anaphase and are not included in daughter cell nuclei 
in the telophase (Ford et al., 1988; Lindholm et al., 1991; 
Ford, Corel, 1992; Catalán, Falck, Norppa, 1973; Falck, 
Catalán, Norppa, 2002).
Formation of MNs in dividing cells is the result of 
chromosome breakage due to loss of repair or no repair of 
DNA lesions, or of poor segregation owing to nondisjunc-
tion in the mitotic apparatus. These events can be induced 
by oxidative stress, exposure to clastogenic or aneugenic 
agents, genetic defects in repair genes and/or cell cycle 
control, as well as deficiency in nutrients required as co-
factors in DNA metabolism and chromosome segregation 
(Kimura et al., 2004; Umegaki, Fenech, 2000; Rajagopa-
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lan et al., 2004; Macgregor, 2005; Fenech et al., 2005). 
All events causing MN formation, such as chromosomal 
rearrangements, gene expression changes or aneuploidy, 
are associated with chromosome instability generally ob-
served in cancer (Rajagopalan et al., 2004; Fenech, 2002; 
Ames, Wakimoto, 2002).
As expected, our results corroborate data from the 
literature confirming the genotoxic effect of cyclophospha-
mide expressed by the increased frequency of micronuclei. 
Cyclophoshamide is an atineoplastic agent with alkylating 
properties, which indiscriminately complexes with DNA 
among normal and cancerous cells and is inactive until it 
is metabolized in the liver by mixed function oxidases of 
the cytochrome P-450 (Valadares, Castro, Cunha, 2007; 
Rang et al., 2003). The acute toxicity of cyclophosphamide 
is primarily associated with its genotoxicity (Krishna; 
Hayashi, 2000). In somatic cells, it provokes gene mu-
tations, chromosomal aberrations, micronuclei and ex-
changes of sister chromatids in a variety of cell cultures 
with and without the presence of metabolic activation 
(Monteith, Vanstone, 1995; Elhajouji et al., 1994; Madle et 
al., 1986). Cyclophosphamide also damages chromosomes 
and micronuclei in the hematopoietic system of rats, mice 
and Chinese hamsters by producing highly reactive carbon 
ions (Moore et al., 1995). 
Other species of the genus Phyllanthus, as P. amarus 
demonstrated antimutagenic properties. Sripanidkulchai 
et al. (2002) demonstrated that P. amarus protects against 
mutagenic effects of 2-aminofluorene, 2-aminoanthracene, 
4-nitroquinoline 1-oxide, N-ethyl-N-nitro-N-nitrosoguani-
dine, 2-nitrofluorene and sodium azide in bacteria testing, as 
well as antagonize DNA damage caused by dimethylnitrosa-
mine in hamster livers. Kumar and Kuttan (2004) reported 
that orally-administered aqueous extract of P. amarus offers 
radioprotection in rats by suppressing the formation of reac-
tive oxygen species (ROS). This detoxifies species induced 
by radiation, increasing restoration and repair processes, 
accelerating hematopoietic recovery and possibly regulat-
ing the activity of response genes. The same authors (2005) 
also demonstrated the chemoprotective activity of 75% P. 
amarus methanolic extract induced by cyclophosphamide 
in mice. The extract significantly lowered myelosuppression 
and improved bone marrow cellularity. It also increased 
glutathione (GSH) and cellular glutathione-S-transferase 
(GST), reducing the toxic effects of cyclophosphamide 
metabolites in the cells. Asare et al. (2012) observed that 
an ethanolic extract obtained from P. niruri was not able to 
promote micronucleus at PCE bone marrow cells of adult 
rats treated with a single dose of 30 or 300 mg/kg. In this 
study, N-ethyl-n-nitrosourea, was employed as positive 
control. After 48h of treatment the animals were killed and 
bone marrow collected for evaluation of genotoxic and 
cytotoxic activities. The authors revealed that the extract 
adopted was not genotoxic or cytotoxic, corroborating with 
the data obtained in the actual study.
In all groups treated only with P. niruri extract, 
PCEMN frequency was similar to the spontaneous 
PCEMN rate of 3 micronuclei per 1000 PCEs (Rabello-
Gay, 1991), found in the negative control group. These 
data suggest the extract does not exhibit mutagenic activ-
ity. Furthermore, our research with dry P. niruri extract 
in doses of 50, 150 and 250 mg/kg of body weight, with 
subchronic oral administration, different as observed in the 
studies mentioned above with P. amarus (Sripani dkulchai 
et al., 2002; Kumar, Kuttan, 2004; Kumar, Kuttan, 2005) 
showed no protective activity in bone marrow cells 
against damage caused by cyclophosphamide. This was 
evidenced by the similar PCEMN frequency between the 
groups treated with the extract + cyclophosphamide and 
the positive control group. The different animal species 
employed in our study (rats) and the above mentioned 
studies (hamster and mice) as well as the plant species and 
the doses and treatment periods may explain the absence 
of effects against damage caused by cyclophosphamide.
CONCLUSIONS
The data revealed here suggest that subchronic oral 
administration of dry P. niruri extract to Wistar rats in the 
three different doses shows low toxicity and exhibits no 
genotoxic or cytotoxic potential in bone marrow cells, or 
chemoprotective properties against damage caused by 
cyclophosphamide. This favors the medicinal use of the 
plant in doses recommended for humans. 
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